PIAS3抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06246(PIAS3 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P06246(PIAS3 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The PIAS3 (Protein Inhibitor of Activated STAT3) antibody is a critical tool for studying the regulatory mechanisms of STAT3 signaling and SUMOylation processes. PIAS3. a member of the PIAS family (PIAS1. PIAS3. PIASx, PIASy), functions as an E3 SUMO ligase that post-translationally modifies target proteins by attaching Small Ubiquitin-like Modifier (SUMO) molecules. It also acts as a transcriptional coregulator, selectively inhibiting STAT3-dependent gene activation by binding directly to phosphorylated STAT3 dimers, thereby blocking their DNA-binding capacity. This interaction plays roles in immune response, cell proliferation, apoptosis, and oncogenesis, with dysregulation linked to cancers, inflammatory diseases, and neurological disorders.

PIAS3 antibodies are widely used in techniques like Western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence to detect PIAS3 expression, localization, and protein interactions. Researchers employ these antibodies to explore PIAS3’s dual roles in SUMOylation-dependent and -independent pathways, its tumor-suppressive or oncogenic functions in different contexts, and its crosstalk with other signaling pathways (e.g., NF-κB, p53). Commercial PIAS3 antibodies are typically raised against specific epitopes (e.g., human PIAS3 amino acids 1-300) and validated for specificity across species (human, mouse, rat). Proper controls (e.g., PIAS3-knockout cell lines) are essential to confirm antibody reliability due to potential cross-reactivity with other PIAS family members.